| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_966a6c1f382ec9bcb5e3839dfd73e5b8 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-94
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-517 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-94 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-517
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2004-02-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2009-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0895ecb83e5051ec939f7882b2c8e0a0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_abc6b923e464236fe157af1bcd790c1d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e58df862b9aa57cc8c981231eb767d97
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_76955b0f2ca2b7a1339d588cb063da21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c179097a619fa9785b622cd02f7fd20f |
| publicationDate |
2009-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
RU-2376294-C2 |
| titleOfInvention |
POLYMORPHOUS MODIFICATION OF COMPOUND {6,7-BIS (2-METHOXYETHOXY)CHINAZOLINE-4-YL}-(3e) |
| abstract |
FIELD: medicine. ^ SUBSTANCE: invention is related to crystalline polymorphous modification of hydrochloride [6,7-bis(2-methoxyethoxy)chinazoline-4-yl]-(3-ethynyl phenyl)amine. Crystalline polymorphous modification has powdery X-ray diffraction pattern, in which there are characteristic maxima, expressed in degrees of angle 2-theta 0.2 degrees: 5.7; 9.7; 10.1; 11.3; 17.0; 17.4; 18.9; 19.6; 21.3; 22.8; 23.6; 24.2; 24.7; 25.4; 26.2; 26.7; 29.3. Invention is also related to method for production of crystalline polymorphous modification, to pharmaceutical composition, having inhibiting action in respect to tyrosine kinase ferments, including crystalline polymorphous modification, to use of crystalline polymorphous modification for preparation of medicinal agents. ^ EFFECT: improved efficiency of compound use. ^ 12 cl, 6 dwg, 9 ex |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2610337-C1 |
| priorityDate |
2003-02-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |